Nanobiotix S.A. (EPA:NANO)
France · Delayed Price · Currency is EUR | Market Cap | 878.47M |
| Revenue (ttm) | 10.16M |
| Net Income (ttm) | -51.64M |
| Shares Out | 48.21M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 402,856 |
| Average Volume | 666,203 |
| Open | 18.42 |
| Previous Close | 18.52 |
| Day's Range | 17.84 - 19.16 |
| 52-Week Range | 2.62 - 19.16 |
| Beta | 1.64 |
| RSI | 83.56 |
| Earnings Date | Sep 18, 2025 |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBT... [Read more]
Financial Performance
Financial StatementsNews
Nanobiotix (NBTX) Sees Stock Rise on Promising Cancer Drug Trial Results
Nanobiotix (NBTX) Sees Stock Rise on Promising Cancer Drug Trial Results
Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug
Top 2 Health Care Stocks That May Keep You Up At Night This Month
As of Oct. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1 st
Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M
Get the latest Nanobiotix S.A. 1H financial results, including GAAP EPS of -€0.11 and revenue of €26.6M.
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approa...
Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer
Nanobiotix SA (NASDAQ: NBTX) on Tuesday announced updated data from cohorts 1 and 2 of Study 1100 Phase 1 dose escalation and expansion trial evaluating JNJ-1900 (NBTXR3) activated by radiation thera...
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Data presented as a “Top-rated Abstract in Head and Neck Cancer” at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on September 29th
Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
Nanobiotix SA NBTX announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study.
Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
Nanobiotix reported melanoma study data showing ... Full story available on Benzinga.com
Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case
Nanobiotix S.A. stock has surged after strong Phase 1 data for NBTXR3 in anti-PD-1 resistant melanoma, showing high response and disease control rates. NBTX's partnership with Janssen could yield up t...
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points on Thursday. Shares of Radian Group Inc . (NYSE: RDN) rose sharply during Thursday's session after the company announce...
Nanobiotix S.A. - Special Call
Nanobiotix S.A. (NBTX) Discusses On New Phase 1 Results In Metastatic Melanoma Conference (Transcript)
Discover promising Phase I trial results for Nanobiotix’s NBTXR3 in refractory melanoma,
Nanobiotix (NBTX) Surges After Promising Phase 1 Results
Nanobiotix (NBTX) Surges After Promising Phase 1 Results
Nanobiotix (NBTX) Surges on Promising Phase 1 Data
Nanobiotix (NBTX) Surges on Promising Phase 1 Data
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1 Recommended phase ...
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based ...
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based appro...
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based ap...
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
PARIS and CAMBRIDGE, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approach...
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based ap...
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in ...
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer | NBTX Stock News
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer Median Overall Surv...
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based ...